icon-folder.gif   Conference Reports for NATAP  
 
  11th International Workshop on Clinical Pharmacology of HIV Therapy
Sorrento, Italy
April 7-9, 2010
Back grey_arrow_rt.gif
 
 
 
GRACE PK Study: Median (range) AUC12h and C0h were similar between women and men, and across black, Hispanic and white patients; Pharmacokinetic results from GRACE demonstrated no clinically relevant differences in exposure to DRV across a range of covariates, including sex, race/ethnicity, use of ETR, use of TDF, age, body weight and hepatitis B co-infection status
 
 
  "Intrinsic/Extrinsic Covariates and Darunavir
Pharmacokinetics in Treatment-Experienced Patients in GRACE (Gender, Race And Clinical Experience)"
 
Reported by Jules Levin
11th International Workshop on Clinical Pharmacology of HIV Therapy (IWCPHIV), Sorrento, Italy, April 7-9, 2010
 
Thomas N. Kakuda, PharmD1, Vanitha J. Sekar, PhD1, Peter Vis, MSc2, Bruce Coate, BS, MPH1, Robert Ryan, MS1, Guy De La Rosa, MD3, Joseph Mrus, MD, MSc3 1Tibotec Inc, Titusville, NJ, USA; 2Tibotec BVBA, Mechelen, Belgium; 3Tibotec Therapeutics, Titusville, NJ, USA
 
AUTHOR CONCLUSIONS
 
Pharmacokinetic results from GRACE demonstrated no clinically relevant differences in exposure to DRV across a range of covariates, including sex, race/ethnicity, use of ETR, use of TDF, age, body weight and hepatitis B co-infection status
 
The results from this study are in agreement with previous findings in DRV/rtv-treated, treatment-experienced HIV-infected patients4,9
 
AUTHOR DISCUSSION
 
The GRACE trial demonstrated that DRV/rtv-based therapy is effective, generally safe and well tolerated across sexes and racial/ethnic groups1,2
- Furthermore, no clinically relevant relationships between DRV PK parameters and the efficacy or safety outcomes of DRV/rtv-based therapy were noted3
 
DRV C0h was above the protein binding corrected EC50 value for resistant virus (550ng/ mL) for all patients, regardless of individual covariates
 
Exposure to DRV was not influenced by sex, race/ethnicity, age, body weight, hepatitis B co-infection status, or use of ETR or TDF
- Differences in AUC12h and C0h between subgroups and across the overall population were small and not considered clinically relevant
 
INTRODUCTION
 
GRACE was a Phase IIIb study specifically designed to enroll a high proportion of treatment-experienced women and people of color to assess sex- and race-based outcomes of a darunavir/ritonavir (DRV/rtv)-based regimen
- Patients received DRV/rtv 600/100mg twice daily plus an optimized background regimen, which could include etravirine (ETR; 200mg twice daily)
 
Of the 429 patients enrolled, virologic response rates (HIV-1 RNA <50 copies/mL) at Week 48 were 53.4% in the intent-to-treat (ITT) population (all patients who took at least one dose of study medication) and 73.2% in the non-virologic failure (non-VF) censored population (censored patients that discontinued for reasons other than VF)1
 
- In the ITT population at Week 48, the virologic response rate was 50.9% in women and 58.5% in men1; the virologic response rates by race were 48.5%, 61.5% and 60.0% in black, Hispanic and white patients, respectively2
- In the non-VF censored population at Week 48, the virologic response rate was 73.0% in women, 73.5% in men, 68.8% in black patients, 79.7% in Hispanic patients and 78.0% in white patients1,2
 
Previously presented results from GRACE showed that there was no relevant relationship between DRV pharmacokinetic (PK) parameters and the efficacy or safety outcomes of DRV/rtv-based therapy,3 consistent with findings from previous studies4,5,6
 
Here we evaluated the effect of extrinsic and intrinsic covariates on DRV PK parameters over 48 weeks of therapy in GRACE
 

aFour patients self-identified as Asian or Other and were not included in the analysis by race; bvirco TYPE HIV-1 resistance analysis; cTwo patients, one Hispanic and one white (both women), did not have resistance testing at baseline; SE, standard error; CDC, US Centers for Disease Control and Prevention; DRV, darunavir; PI, protease inhibitor

Intensive PK sampling from 32 patients showed no time-dependent relationship for DRV exposure over 48 weeks and demonstrated results similar to the population PK results (Figure 3)

Use of ETR or TDF, hepatitis B co-infection status, age or body weight did not affect DRV AUC12h or C0h (Table 2)

REFERENCES
 
1. Squires K, et al. Poster presented at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22, 2009. Poster MOPEB042.
 
2. Smith K, et al. Poster presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 12-15, 2009. Poster H-918.
 
3. Sekar V, et al. Presented at the 12th European AIDS Conference (EACS), Cologne, Germany, November 11-14, 2009. Poster PE4.1/8.
 
4. Sekar V, et al. Oral presentation at the 11th European AIDS Conference, Madrid, Spain, October 24-27, 2007. Abstract PS4/5.
 
5. Sekar V, et al. Poster presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, February 3-6 2008. Poster 769.
 
6. Sekar V, et al. Poster presented at the 16th International Aids Conference (AIDS 2006); Toronto, Canada, August 13-18, 2006. Poster TUPE0078.
 
7. Vis P, et al. Poster presented at the 15th Population Approach Group in Europe, Bruges, Belgium, June 14-16, 2006. Poster 964.
 
8. Scholler-Gyure et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12:789-726
 
9. Sekar V. Poster presented at the 9th International Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, LA, USA, April 7-9, 2008. Poster P41.